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Materials and Methods: From January 2011 to December 
2013, 155 patients (97 male / 58 female) who had 
histopathologically confirmed NPC treated in our department 
with definitive-intent RT to a dose of 54 – 57 Gy (3 Gy daily 
fraction) for nasopharyngeal tumour and positive neck lymph 
nodes. The dose for the prevention irradiation of negative 
neck lymph nodes was 36 – 51 Gy (3 Gy daily fraction). 
Results: Mean age was 44.9 ± 1.1 years (Range 16-81). Stage 
I, II, III, IVA and IVB (UICC 2009) were 7, 32, 40, 51 and 25 
respectively. 118 patients received induction chemotherapy 
platinum-based. Commonest adverse effects (NCI-CTC 4.0) 
were: mucositis, dysphagia, and dermatisis. Grade 3 or 4 
mucositis, dysphagia, dermatisis occurred in 16 cases (10.3%), 
15 cases (9.7%) and 4 cases (2.6%) respectively. Response 
rate of 154 patients were (1 patient was refused evaluation): 
complete response 65.6%, Partial response 24.1%, stable 
disease 7.1% and progressive disease 3.2%. With median 
follow-up of 18 months, 10 and 15 patients were presented 
locoregional recurrence and metastasis respectively. The 
locoregional control (LRC), Metastasis free survival (MFS), 
disease free survival (DFS) and overall survival (OS) rates at 
one year were: 95.8% (±1.8%), 89.3% (±2.6%), 85.2 % (±3.1%) 
and 93.9% (±2.1%), respectively. 
Conclusions: Preliminary findings using a hypofractionated 
scheme is a feasible option in the treatment of NPC (an 
effective regimen with an acceptable safety profile). 
However, an important number of patients and a longer 
follow-up are necessary to better appreciate the efficacy and 
the toxicity outcome (late effect) of this scheme.  
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Purpose/Objective: Currently, during the delivery of the 
Rapid Arc® (RA)/Volumetric Modulated Arc Therapy (VMAT) 
plan, the jaws are fixed allowing the possibility of radiation 
leaking in-between leaves and in-between the leaves gaps 
from opposite pairs. The purpose of this work is to evaluate 
the potential improvement in Rapid Arc plans dosimetry when 
plan delivery allows for jaw tracking. This work represents 
one of the initial attempts to assess the usefulness of 
evaluating normal tissue dose reduction in dynamic VMAT on 
the True beam STx platform by tracking the multi-leaf 
collimator (MLC) apertures with the accelerator jaws. 
Materials and Methods: We use the Eclipse (version 10.4) and 
Truebeam STx linear accelerator which allows jaw tracking 
during VMAT delivery for both the X and Y jaws. We 
considered, Brain, Head & Neck patients. We set the 
collimator between 15oand 30o and generate plans with and 
without jaw tracking for comparison. Special attention is 
given to the low dose regions where more noticeable 
differences were expected.Clinical radiation treatment plans 
for Brain, Head and Neck patients were converted to plans 
with the jaws tracking. Each plan without jaw tracking were 
planned to obtain target coverage within 1% of that in the 
original jaw tracking plan. The new plans were compared to 
the original plans in a Varian Eclipse treatment planning 
system (TPS). Reduction in normal tissue dose was evaluated 
in the new plan by using the parameters V5, V10, and V20 in 
the cumulative dose-volume histogram for the following 
structures: Brainstem, Spinal cord, Parotids. Cochlea, Oral 
Cavity, Larynx, Mandible In order to validate the accuracy of 
our beam model, MLC transmission measurements were made 
and compared to those predicted by the TPS. 
Results: The greatest change between the original plan and 
new plan occurred at lower dose levels. The reduction in V20 
was never more than 3.7% and was typically less than 1% for 
all patients. The reduction in V10 was never more than 6.9% 
and was typically less than 1.5% for all patients. The 
reduction in V5 was 1.4% maximum and was typically less 
than 0.5% for all patients. The variation in normal tissue dose 
reduction was not predictable, and we found no clear 
parameters that indicated which patients would benefit most 
from jaw tracking. Our TPS model of MLC transmission agreed 
with measurements with absolute transmission differences of 
less than 0.1 % and thus uncertainties in the model did not 
contribute significantly to the uncertainty in the dose 
determination 
Conclusions: The amount of dose reduction achieved by 
collimating the jaws around each MLC aperture in VMAT 
appears to be similar and not more than 2%. Currently we are 
analysing more plans for other sites and with other 
geometries to improve the statistical significance of our 
conclusion. 
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Purpose/Objective: The aim of the work was to assess the 
significance of beta-tubulin II (βT-II) expression as a 
predictive marker for clinical response to neoadjuvant TPF 
chemotherapy (Docetaxel, Cisplatin, Fluorouracil) in locally 
advanced squamous cell head and neck cancers (LASHNC). 
Materials and Methods: A group of 31 patients, without 
distant metastasis, with LASHNC in clinical stage III or IV of 
disease, not qualified primary for concurrent chemoradiation 
because of large primary tumor or bulky neck lymph nodes 
metastases, was analyzed retrospectively. In the therapy, 2–3 
cycles of neoadjuvant TPF chemotherapy were used, 
followed by radiotherapy or chemoradiotherapy in all 
patients. The tumor response to neoadjuvant therapy was 
assessed according to RECIST vs 1.1, based on the results of 
facial skeleton CT scanning before and after the 
chemotherapy. Using immunohistochemical method, the 
presence of βT-II in the tumor tissue was assayed in paraffin-
embedded, archive tissue material collected from the 
patients before the start of the therapy. A computer analysis 
of IHC reaction image was performed using DensitoQuant 
software (3DHISTECH, Hungary). The high expression 
threshold was defined as presence of >17% of moderate and 
strong reactions in the specimen. The clinical response to 
TPF chemotherapy as categorized according to RECIST and by 
percentage of measurable lesions regression, in the context 
of level of βT-II in cancer cells was analyzed. 
Results: 12 specimens (38.7%) were classified to high and 19 
specimens (61.3%) to low protein expression group. Partial 
regression (PR) of lesions after neoadjuvant chemotherapy 
3rd ESTRO Forum 2015                                                                                                                                         S621 
 
was found in 21 patients (67.8%) and stable disease (SD) was 
observed in 10 cases (32.2%). SD after chemotherapy was 
reported more often in patients qualified to high expression 
of βT-II, whereas PR in the group of low protein expression 
(p=0.004). The increase in Histoscore (HS) parameter 
obtained from the computer image analysis was correlated 
with the observed lower regression of the tumor (r=–0.43, 
p=0.017). In patients with SD effect observed after induction 
chemotherapy the mean value of HS was 109.5 whereas in 
the PR group the mean value of HS was 28.34. No correlation 
between the response to radiotherapy and βT-II expression 
was found (p=0.92). The difference in 1-year OS and PFS was 
not shown for the patients from neither the high or low βT-II 
expression (OS 75% vs 63%; p=0.69, PFS 63% vs 58%; p=0.69). 
Conclusions: The βT-II protein expression level in tumor 
tissue is a predictive factor for clinical response to taxane-
based neoadjuvant chemotherapy in LASHNC. In the case of 
high βT-II expression the most probable effect of 
chemotherapy is tumor stabilization. Low βT-II expression 
level may be a parameter used to select the patients with 
prognozed good response to TPF chemotherapy. In these 
patients realization of radiotherapy may be easier without 
the risk of delayed definitive treatment.  
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Purpose/Objective: To investigate effects of the epidermal 
growth factor receptor (EGFR) polymorphisms on survival for 
advanced oral cancer patients. 
Materials and Methods: A total of 156 patients with 
advanced oral cancer were treated with a uniform induction 
chemotherapy (Methotrexate 30 mg/m2 D1, Epirubicin 30 
mg/m2 D1, alternating with Mitomycin-C 4 mg/m2 D8, 
Oncovin 1 mg/m2 D8, Cisplatin 25 mg/m2 D8, Leucovorin 120 
mg/m2 D8, 5-fluorouracil 1000 mg/m2 D8, and Bleomycin 10 
mg/m2 D8) for 8-12 weeks followed by local treatment 
(surgery/radiotherapy). Most patients (97.5%) belonged to 
stage IV and 70% presented with unresectable tumor. DNA 
extracted from peripheral blood cells of each patient were 
used for genotyping. Four EGFR polymorphisms, codon 497 
(R497K), CA simple sequence repeat 1 (CA-SSR1) in intron 
one, and two single nucleotide polymorphisms in the 
promoter region (-216 G to T and -191 C to A) were 
examined. Overall survival (OS) and locoregional failure-free 
survival (LRFFS) according to EGFR polymorphisms were 
analyzed. 
Results: The frequencies of the R/R, R/K, and K/K genotypes 
for R497K polymorphism were 26.3%, 48.7%, and 25.0%, 
respectively. The G/G, G/T, and T/T genotypes distribution 
for the -216 G to T polymorphism showed 91.0%, 7.7%, and 
1.3%, respectively. Most patients (86.5%) belong to a longer 
CA repeats (>35 repeat) genotype. For the -191 C to A 
polymorphism, 100% patients were C/C type. Patients with 
heterozygosity of EGFR codon 497 (Arg/Lys) showed better 
survivals (5-year OS=34.9% vs. 23.1%, P=0.1545; 5-year 
LRFFS=46.2% vs. 24.9%, P=0.0663) than those of homozygosity 
(Arg/Arg or Lys/Lys). Better survivals were observed in 
patients with variant SNP -216 G/G genotype than those of -
216 G/T or T/T genotypes (5-year OS=29.4% vs. 11.0%, 
P=0.0661; 5-year LRFFS=36.9% vs. 11.2%, P=0.0179). 
Combined both R497K and -216 G to T polymorphisms have 
more significant effects on OS (P=0.014) and LRFFS (P=0.010). 
The lengths of CA-SSR1 repeats did not affect survival. 
Conclusions: Combination of the R497K and -216 G to T 
polymorphisms of the EGFR is a significant prognostic factor 
in predicting survival for patient with advanced oral cancer. 
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Purpose/Objective: The aim of the study was to report the 
long-term clinical outcomes of nasopharynx cancer patients 
treated with cisplatin based concurrent chemoradiation 
(RCT). 
Materials and Methods: Patients with nasopharynx tumor 
(UICC Stage II-IV) treated with definitive RCT or neoadjuvant 
chemotherapy (NACT: Cisplatin + 5-Fluorouracil (CF) or 
Docetaxel + Cisplatin + 5-Fluorouracil (DCF)) followed by RCT 
from January 2006 to January 2014 were included in the 
analysis. According to a dose-escalation protocol, a total of 
67.5-70.5 Gy in 30 fractions were delivered to primary tumor 
and involved nodes, 60 Gy in 30 fractions to high-risk nodal 
areas, and 55.5 Gy in 30 fractions to low-risk nodal areas. 
Simultaneous integrated boost IMRT/VMAT technique was 
used. Local control and overall survival were estimated by 
the Kaplan-Meier method. 
Results: 26 patients (M/F: 19/7; median age: 55 years; 
range: 30-79 years; UICC stage: II (3 patients), III (8 patients) 
and IV (15 patients)) were treated and analyzed. 3 cycles of 
NACT (CF or DCF) was administered in 21 patients (81%). 15 
patients were treated with IMRT/SIB and 11 with VMAT/SIB. 
Grade 3 or 4 acute toxicities (RTOG score) were: oral 
mucositis (8 patients: 31%); dysphagia (1 patient: 4%); 
dysphonia (2 patients: 8%); hematological suppression (6 
patients: 23%). No Grade 3 or 4 late toxicity (RTOG EORTC 
score) was recorded. The 2- and 5-year local control were 
84% and 60% and 2- and 5-year overall survival were 75% and 
44%, respectively. 
Conclusions: In our experience, a moderately accelerated 
concurrent RCT, even after induction chemotherapy, is 
feasible and well tolerated. Taking into account the 
